Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,822,753
  • Shares Outstanding, K 56,773
  • Annual Sales, $ 26,820 K
  • Annual Income, $ -352,090 K
  • 60-Month Beta 0.79
  • Price/Sales 101.07
  • Price/Cash Flow N/A
  • Price/Book 3.64
Trade AGIO with:

Options Overview Details

View History
  • Implied Volatility 48.99% ( -1.17%)
  • Historical Volatility 41.50%
  • IV Percentile 63%
  • IV Rank 59.45%
  • IV High 80.83% on 05/31/24
  • IV Low 2.31% on 11/14/23
  • Put/Call Vol Ratio 0.42
  • Today's Volume 118
  • Volume Avg (30-Day) 141
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 7,125
  • Open Int (30-Day) 7,658

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.57
  • Number of Estimates 6
  • High Estimate -1.45
  • Low Estimate -1.69
  • Prior Year -1.51
  • Growth Rate Est. (year over year) -3.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.79 +21.88%
on 07/09/24
50.35 -1.25%
on 07/23/24
+4.50 (+9.95%)
since 06/21/24
3-Month
31.00 +60.39%
on 05/24/24
50.35 -1.25%
on 07/23/24
+17.91 (+56.30%)
since 04/23/24
52-Week
19.80 +151.17%
on 10/27/23
50.35 -1.25%
on 07/23/24
+22.20 (+80.67%)
since 07/21/23

Most Recent Stories

More News
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fall

CORT : 34.56 (-0.03%)
ET : 16.40 (+0.12%)
USM : 54.01 (-3.33%)
AY : 22.08 (-0.54%)
DKNG : 37.78 (+2.55%)
AGIO : 49.72 (+4.13%)
INSM : 75.99 (-0.38%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 49.72 (+4.13%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 49.72 (+4.13%)
Agios Pharmaceuticals: Q2 Earnings Snapshot

Agios Pharmaceuticals: Q2 Earnings Snapshot

AGIO : 49.72 (+4.13%)
Why Shares of Schrödinger Rose This Week

Interest in the company's AI platform continues to drive the stock.

AGIO : 49.72 (+4.13%)
GS : 492.15 (+1.05%)
SDGR : 22.67 (-2.33%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 49.72 (+4.13%)
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

/PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment...

AGIO : 49.72 (+4.13%)
3 Under-the-Radar Biotech Stocks to Buy in 2022

The attraction of all three biotech stocks is their potential.

ATRA : 10.43 (+2.96%)
AGIO : 49.72 (+4.13%)
BEAM : 30.32 (+12.09%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 49.72 (+4.13%)
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering...

AGIO : 49.72 (+4.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 54.38
2nd Resistance Point 52.36
1st Resistance Point 51.04
Last Price 49.72
1st Support Level 47.71
2nd Support Level 45.69
3rd Support Level 44.37

See More

52-Week High 50.35
Last Price 49.72
Fibonacci 61.8% 38.68
Fibonacci 50% 35.07
Fibonacci 38.2% 31.47
52-Week Low 19.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar